Physician profile
Scott E Harrison
NPI 1992894653
$1,221.89
in general payments reported to CMS, 2019-2025
20 companies · $102 in 2025
The $102 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $378 · 2020: $137 · 2021: $103 · 2022: $294 · 2023: $146 · 2024: $61.13 · 2025: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $309.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $268.58 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $268.26 | 2019-2024 | Jardiance, Synjardy, Trijardy Xr |
| Inspire Medical Systems, INC. | $130.70 | 2019 | |
| Glaxosmithkline, LLC. | $91.34 | 2024-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Medtronic, INC. | $70.40 | 2022 | |
| Aerin Medical INC. | $66.39 | 2021-2023 | |
| Olympus America INC. | $52.01 | 2020-2023 | Rhino-Laryngo Videoscope |
| Stryker Corporation | $43.89 | 2020-2021 | |
| Genzyme Corporation | $42.51 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.54 | 2019-2022 | |
| Boston Scientific Corporation | $22.68 | 2025 | Wavewriter Alpha Prime 16 |
| Ardelyx, INC. | $21.64 | 2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $18.09 | 2019 | |
| Allergan, INC. | $17.35 | 2020 | |
| Gilead Sciences, INC. | $15.33 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $15.04 | 2023 | Cologuard Collection Kit |
| Intersect Ent, INC. | $13.51 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $12.96 | 2023 | Rexulti |
| Abbvie INC. | $12.70 | 2022 | |
| Genentech USA, INC. | $11.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.